Avenue Therapeutics, Inc.

BST:49Y0 Stock Report

Market Cap: €3.4m

Avenue Therapeutics Future Growth

Future criteria checks 0/6

Avenue Therapeutics is forecast to grow earnings and revenue by 7.9% and 85.7% per annum respectively while EPS is expected to grow by 31.3% per annum.

Key information

7.9%

Earnings growth rate

31.3%

EPS growth rate

Pharmaceuticals earnings growth21.6%
Revenue growth rate85.7%
Future return on equityn/a
Analyst coverage

Low

Last updated02 Apr 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BST:49Y0 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-20-20N/A1
12/31/2025N/A-16-16N/A1
12/31/2024N/A-13-13N/A1
12/31/2023N/A-10-12-9N/A
9/30/2023N/A-10-14-11N/A
6/30/2023N/A-12-13-11N/A
3/31/2023N/A-8-7-7N/A
12/31/2022N/A-4-8-8N/A
9/30/2022N/A-5-5-5N/A
6/30/2022N/A-5-5-5N/A
3/31/2022N/A-6-4-4N/A
12/31/2021N/A-4-4-4N/A
9/30/2021N/A-4-4-4N/A
6/30/2021N/A-4-4-4N/A
3/31/2021N/A-5-5-5N/A
12/31/2020N/A-5-5-5N/A
9/30/2020N/A-10-8-8N/A
6/30/2020N/A-11-9-9N/A
3/31/2020N/A-16-22-22N/A
12/31/2019N/A-26-26-26N/A
9/30/2019N/A-24-23-23N/A
6/30/2019N/A-25-25-25N/A
3/31/2019N/A-22-17-17N/A
12/31/2018N/A-22-18-18N/A
9/30/2018N/A-24-21-21N/A
6/30/2018N/A-24-19-19N/A
3/31/2018N/A-22-14-14N/A
12/31/2017N/A-12-7-7N/A
9/30/2017N/A-7N/A-3N/A
6/30/2017N/A-4N/A-1N/A
3/31/2017N/A-3N/A-1N/A
12/31/2016N/A-3N/A-2N/A
9/30/2016N/A-4N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 49Y0 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 49Y0 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 49Y0 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 49Y0 is forecast to have no revenue next year.

High Growth Revenue: 49Y0 is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 49Y0's Return on Equity is forecast to be high in 3 years time


Discover growth companies